The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L‐29) on pain behaviour in rodent models of neuropathy
- 1 August 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (7) , 1117-1128
- https://doi.org/10.1038/sj.bjp.0707326
Abstract
Background and Purpose: Cannabinoids are associated with analgesia in acute and chronic pain states. A spectrum of central cannabinoid (CB1) receptor‐mediated motor and psychotropic side effects limit their therapeutic potential. Here, we investigate the analgesic effect of the palmitoylethanolamide (PEA) analogue, palmitoylallylamide (L‐29), which via inhibition of fatty acid amide hydrolase (FAAH) may potentiate endocannabinoids thereby avoiding psychotropic side effects.Experimental Approach: Thein vivoanalysis of the effect of L‐29 on measures of pain behaviour in three rat models of neuropathic pain.Key Results: Systemically administered L‐29 (10 mg kg−1) reduced hypersensitivity to mechanical and thermal stimuli in the partial sciatic nerve injury (PSNI) model of neuropathic pain; and mechanical hypersensitivity in a model of antiretroviral (ddC)‐associated hypersensitivity and a model of varicella zoster virus (VZV)‐associated hypersensitivity. The effects of L‐29 were comparable to those of gabapentin (50 mg kg−1). The CB1receptor antagonist SR141716a (1 mg kg−1) and the CB2receptor antagonist SR144528 (1 mg kg−1) reduced the effect of L‐29 on hypersensitivity in the PSNI and ddC models, but not in the VZV model. The peroxisome proliferator‐activated receptor‐α antagonist, MK‐886 (1 mg kg−1), partially attenuated the effect of L‐29 on hypersensitivity in the PSNI model. L‐29 (10 mg kg−1) significantly attenuated thigmotactic behaviour in the open field arena without effect on locomotor activity.Conclusions and Implications: L‐29 produces analgesia in a range of neuropathic pain models. This presents L‐29 as a novel analgesic compound that may target the endogenous cannabinoid system while avoiding undesirable side effects associated with direct cannabinoid receptor activation.British Journal of Pharmacology(2007)151, 1117–1128; doi:10.1038/sj.bjp.0707326Keywords
This publication has 87 references indexed in Scilit:
- Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathyPain, 2007
- Inhibitors of monoacylglycerol lipase as novel analgesicsBritish Journal of Pharmacology, 2007
- Further characterization of a rat model of varicella zoster virus–associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugsNeuroscience, 2006
- Endocannabinoid mechanisms of pain modulationThe AAPS Journal, 2006
- Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-αThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic ReviewPLoS Medicine, 2005
- The search for the palmitoylethanolamide receptorLife Sciences, 2005
- Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid CeramidaseJournal of Biological Chemistry, 2005
- Peripheral neuropathic pain—a multidimensional burden for patientsEuropean journal of pain, 2001
- Ethical guidelines for investigations of experimental pain in conscious animalsPAIN®, 1983